Press release
2023 Ovarian Cancer Drugs Market Research Report: Market Size, Demand, Insights and Analysis 2032 | AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Amgen Inc, Bristol-Myers Squibb Company
Ovarian Cancer Drugs Market
The increase in geriatric population is a major driver for the ovarian cancer drugs market as age is a key risk factor for ovarian cancer, with two-thirds of ovarian cancers occurring in women over the age of 55. Geriatric population often suffer with various diseases because of their age factor and most of the women aged above 65 suffer with ovarian related problems. For example, according to ACL (Administration For Community Living), a US-based government organization, the geriatric population is expected to increase by 21.6% by 2040.Therefore, increasing geriatric population will drive the ovarian cancer drugs market going forward.
View Complete Report @
https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-market
The antibody-drug conjugates or ADCs consist of a drug linked to an antibody that directly targets the cancer cell. Antibody-drug conjugates are novel therapeutic agents designed to target antigens specific to ovarian tumor cells with direct delivery of cytotoxic agents to combat recurrent, platinum-resistant disease while limiting systemic toxicity. As the field of targeted therapy continues to evolve, continued development of target antigens and ADCs are likely to represent a key development in treatment of ovarian cancer. Mirvetuximab soravtansine by ImmunoGen Inc., a US-based biotechnology company, is the only ADC that has been evaluated in a phase 3 trial. Mirvetuximab connects an antibody targeting the folate receptor alpha molecule on high-grade serous ovarian cancers to a drug molecule called DM4 that disrupts microtubule formation.
The top opportunities in the ovarian cancer drugs market segmented by drug type will arise in the alkylating agents market segment, which will gain $1,679.2 million of global annual sales by 2026. The top opportunities in the ovarian cancer drugs market segmented by tumor type will arise in the epithelial ovarian cancer market segment, which will gain $2,639.9 million of global annual sales by 2026. The top opportunities in the ovarian cancer drugs market segmented by distribution channel will arise in the drug stores market segment, which will gain $1,747.4million of global annual sales by 2026. The top opportunities in the ovarian cancer drugs market size will gain the most in USA at $1,027.6 million.
Ovarian Cancer Drugs Market Segmentation:
The Ovarian Cancer Drugs market is segmented by drug type, by tumor type and by distribution channel.
By Drug Type-
The ovarian cancer drugs market is segmented by drug type into
a) Alkylating Agents
b) Mitotic Inhibitors
c) VEGF/VEGFR Inhibitors
By Tumor Type-
The ovarian cancer drugs market is segmented by tumor type into
a) Epithelial Ovarian Cancer
b) Germ Cell Ovarian Cancer
c) Stromal Cell Ovarian Cancer
By Distribution Channel
The ovarian cancer drugs market is segmented by distribution channel into
a) Hospital Pharmacies
b) Drug Stores
c) Other Distribution Channels
Major players in the Ovarian Cancer Drugs market include AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Amgen Inc, Bristol-Myers Squibb Company.
The regions covered in the global Ovarian Cancer Drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Download FREE SAMPLE Report - https://www.thebusinessresearchcompany.com/sample_request?id=8432&type=smp
The latest report from The Business Research Company, 'Global Ovarian Cancer Drugs Opportunities And Strategies Market Report - Forecast To 2032,' provides a comprehensive global perspective with data and statistics from 60+ geographies, analyzing 7000+ market segments. The regional and country breakdowns section offers insights into each geography's market analysis, size, historic and forecast growth, and key strategies for industry competitiveness.
Ovarian Cancer Drugs Market Report Table Of Content
1. Executive Summary
2. Table of Contents
3. List of Figures
4. List of Tables
5. Report Structure
……
20. Pipeline Analysis
21. Key Mergers and Acquisitions
22. Opportunities And Strategies
23. Ovarian Cancer Drugs Market, Conclusions And Recommendations
24. Appendix
PURCHASE the report @
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8432
Get to know us better:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release 2023 Ovarian Cancer Drugs Market Research Report: Market Size, Demand, Insights and Analysis 2032 | AstraZeneca plc, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Amgen Inc, Bristol-Myers Squibb Company here
News-ID: 3271765 • Views: …
More Releases from The Business research company
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Company Registration Service Market Through 2025?
The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth…
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025?
In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of…
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025?
The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in…
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025?
In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth…
More Releases for Ovarian
Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
Ovarian Cancer Drugs Market Report 2020-2030
Forecasts by Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors) Plus Analysis of Leading Companies
Download free sample pages: https://www.visiongain.com/report/ovarian-cancer-drugs-market-report-2020-2030/
Ovarian Cancer Drugs Market- our new study reveals trends, R&D progress, and predicted revenues
Where the Ovarian Cancer Drugs is market heading? If you are involved in this industry you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
Discover…
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body.
The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in…
